Chronic myelogenous leukemia (CML) is a myeloproliferative stem cell disorder associated with the BCR-ABL tyrosine kinase oncogene. Genomic instability in CML is thought to ultimately cause progression of the disease and therapy-related drug resistance. The underlying molecular mechanisms that cause BCR-ABL transformed hematopoietic stem cells to be susceptible to genomic instability are unknown. Reactive oxygen species (ROS) have already been shown to generate DNA adducts and cause oxidative DNA damage, which can result in genomic mutations. A subsequent lack of appropriate repair is a major cause of genomic instability. In addition, relative levels of ROS are tightly regulated in normal hematopoiesis and are part of homeostatic mechanisms but they are chronically elevated in many cancers, including CML. We have shown that BCR-ABL regulates generation of ROS in the mitochondria through a hyperactive glucose metabolism. We propose to define signaling requirements that lead to abnormal regulation of the glycolytic pathway in BCR-ABL transformed cells, required to maintain high levels of ROS. We will use pre-clinical models of CML as well as normal and CML CD34+ stem cells. The main hypothesis to be tested is that hyperactive glucose metabolism in BCR-ABL transformed cells is sufficient for the induction of DNA damage through ROS and that targeting pathways which lead to increased glucose metabolism-dependent ROS production by BCR-ABL will ultimately decrease genomic instability. We will (1) define the molecular requirements for BCR-ABL?induced oxidative DNA damage;(2) define abnormalities in signaling pathways in BCR-ABL transformed cells, regulated through the autophosphorylation site Tyr177 in BCR-ABL;(3) determine the efficacy of targeted approaches for the prevention of DNA mutations and the induction of imatinib resistance. Understanding the causes and consequences of ROS production in leukemia are likely to lead to the identification of novel therapeutic targets in the disease and may help to overcome drug-resistance. It is anticipated that these results will also improve the understanding of the role of ROS in leukemic transformation, as well as in normal hematopoietic signaling. Our results will also have relevance to others cancers, since elevated ROS and genomic instability are common among transformed cells. Project Narrative Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disease caused by the BCR-ABL oncogene. Transformation by BCR-ABL is associated with a hyperactive glucose metabolism, increased reactive oxygen species (ROS) production and genomic instability. This proposal aims to evaluate the role of these unique phenomena in oxidative DNA damage and genomic mutations, ultimately leading to a better understanding of the biology of CML.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Mufson, R Allan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Salgia, Ravi; Sattler, Martin (2013) A new hope for precision medicine. Sci Transl Med 5:208fs38
Toms, Angela V; Deshpande, Anagha; McNally, Randall et al. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol 20:1221-3
Reddy, Mamatha M; Deshpande, Anagha; Sattler, Martin (2012) Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets 16:313-24
Nieborowska-Skorska, Margaret; Kopinski, Piotr K; Ray, Regina et al. (2012) Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119:4253-63
Deshpande, A; Reddy, M M; Schade, G O M et al. (2012) Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 26:708-15
Talbot, Anne-Laure; Bullock, Grant C; Delehanty, Lorrie L et al. (2011) Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling. PLoS One 6:e23850
Naramura, Mayumi; Nadeau, Scott; Mohapatra, Bhopal et al. (2011) Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget 2:245-50
Weisberg, Ellen; Ray, Arghya; Nelson, Erik et al. (2011) Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One 6:e25351
Reddy, M M; Fernandes, M S; Salgia, R et al. (2011) NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia 25:281-9
Fernandes, Margret S; Reddy, Mamatha M; Croteau, Nicole J et al. (2010) Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 285:32596-605

Showing the most recent 10 out of 13 publications